We are delighted to present the inaugural Frontiers in Pharmacology “Women in Pharmacology of Anti-Cancer Drugs 2021” series of article collections. This is part of series that we are hosting throughout Frontiers in Pharmacology:
Women in Obstetric and Pediatric Pharmacology: 2021Women in Inflammation Pharmacology: 2021Women in Integrative and Regenerative Pharmacology: 2021Women in Pharmacology of Infectious Diseases: 2021Women in Drug Metabolism and Transport: 2021At present, according to
UNESCO, less than 30% of researchers worldwide are women. Long-standing biases and gender stereotypes are discouraging girls and women away from science-related fields, and STEM research in particular. Science and gender equality are, however, essential to ensure sustainable development as highlighted by UNESCO. In order to change traditional mindsets, gender equality must be promoted, stereotypes defeated, and girls and women should be encouraged to pursue STEM careers.
Therefore,
Frontiers in Pharmacology is proud to offer this platform to promote the work of women scientists, across all areas of Pharmacology of Anti-Cancer Drugs.
The work presented here highlights the diversity of research performed across the entire breadth of Pharmacology research and presents advances in theory, experiment, and methodology with applications to compelling problems.
Please note: we especially welcome manuscripts where to be considered for this collection, the first or last author should be a researcher who identifies themselves as a woman.
Different Article Types can be submitted to the Research Topic including Original Research, Review, Mini-Review, Brief Research Report, Perspective articles, among others. You can find detailed information
here.
Important Note: All contributions to this Research Topic must be within the scope of the section Pharmacology of Anti-Cancer Drugs and Journal Frontiers in Pharmacology, as defined in their mission statements (learn more
here).
Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
We are delighted to present the inaugural Frontiers in Pharmacology “Women in Pharmacology of Anti-Cancer Drugs 2021” series of article collections. This is part of series that we are hosting throughout Frontiers in Pharmacology:
Women in Obstetric and Pediatric Pharmacology: 2021Women in Inflammation Pharmacology: 2021Women in Integrative and Regenerative Pharmacology: 2021Women in Pharmacology of Infectious Diseases: 2021Women in Drug Metabolism and Transport: 2021At present, according to
UNESCO, less than 30% of researchers worldwide are women. Long-standing biases and gender stereotypes are discouraging girls and women away from science-related fields, and STEM research in particular. Science and gender equality are, however, essential to ensure sustainable development as highlighted by UNESCO. In order to change traditional mindsets, gender equality must be promoted, stereotypes defeated, and girls and women should be encouraged to pursue STEM careers.
Therefore,
Frontiers in Pharmacology is proud to offer this platform to promote the work of women scientists, across all areas of Pharmacology of Anti-Cancer Drugs.
The work presented here highlights the diversity of research performed across the entire breadth of Pharmacology research and presents advances in theory, experiment, and methodology with applications to compelling problems.
Please note: we especially welcome manuscripts where to be considered for this collection, the first or last author should be a researcher who identifies themselves as a woman.
Different Article Types can be submitted to the Research Topic including Original Research, Review, Mini-Review, Brief Research Report, Perspective articles, among others. You can find detailed information
here.
Important Note: All contributions to this Research Topic must be within the scope of the section Pharmacology of Anti-Cancer Drugs and Journal Frontiers in Pharmacology, as defined in their mission statements (learn more
here).
Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
